Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
The combination of BOT/BAL demonstrated promising efficacy and safety in a large cohort of heavily pretreated sarcoma patients. This encouraging activity warrants further investigation (ClinicalTrials.gov identifier: NCT03860272).
Authors
- Jonathan C. Trent (ORCID: https://orcid.org/0000-0001-6169-5238)
- Breelyn A. Wilky (ORCID: https://orcid.org/0000-0001-5080-497X)
- Gary K. Schwartz (ORCID: https://orcid.org/0000-0003-1813-5061)
- Benny Johnson (ORCID: https://orcid.org/0000-0003-3683-8115)
- Anthony B. El-Khoueiry (ORCID: https://orcid.org/0000-0002-9053-3841)
- Wei Wu
- Mark Agulnik (ORCID: https://orcid.org/0000-0003-3513-3519)
- Daruka Mahadevan (ORCID: https://orcid.org/0000-0002-2991-0361)
- Arun S. Singh (ORCID: https://orcid.org/0000-0002-1633-7746)
- Apostolia Maria Tsimberidou (ORCID: https://orcid.org/0000-0003-2713-233X)
- Manushak Avagyan (ORCID: https://orcid.org/0000-0003-2207-3107)
- Robin L. Jones (ORCID: https://orcid.org/0000-0003-4173-3844)
- Steven O’Day (ORCID: https://orcid.org/0009-0005-5345-5417)
- Michael S. Gordon (ORCID: https://orcid.org/0000-0002-7679-9504)
- Andrea J. Bullock (ORCID: https://orcid.org/0000-0001-7143-0225)
- Joseph E. Grossman (ORCID: https://orcid.org/0000-0002-2130-2783)
- Justin Stebbing (ORCID: https://orcid.org/0000-0002-1117-6947)
- Brian S. Henick (ORCID: https://orcid.org/0000-0003-2681-0805)
- Dhan Chand (ORCID: https://orcid.org/0009-0003-8124-4399)
- Chloé Delépine (ORCID: https://orcid.org/0000-0002-1856-9583)
Institutions
- University of Southern California (US)
- Beth Israel Deaconess Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Institute of Cancer Research (GB)
- University of Miami (US)
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Agenus (United States) (US)
- Royal Marsden Hospital (GB)
- HonorHealth (US)
- University of Colorado Cancer Center (US)
- Sylvester Comprehensive Cancer Center (US)
- Case Comprehensive Cancer Center
- Anglia Ruskin University (GB)
- Columbia University (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1200/jco-24-02524
- Citations
- 16
- Primary Topic
- Vascular Tumors and Angiosarcomas
- Type
- article
- Field-Weighted Citation Impact
- 15.68